Phaseline

Companies › MRM Health

MRM Health: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Immunology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
High-dose MH002
Live biotherapeutic product containing 6 wildtype commensal bacterial strains
–Phase 2Colitis, UlcerativeSep 2027
Low-dose MH002
Live biotherapeutic product containing 6 wildtype commensal bacterial strains
–Phase 2Colitis, UlcerativeSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07296315Low-dose MH002Phase 2Colitis, UlcerativeImmunologySep 2027
NCT07296315High-dose MH002Phase 2Colitis, UlcerativeImmunologySep 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Triveni Bio Citryll Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Navigator Medicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.